Myositis diagnosis and management

Practical Neurology

Volumn 2, Issue 1, 2002, Pages 4-11

  Chevrel, Guillaume ^a   Goebels, Norbert ^b   Hohlfeld, Reinhard ^b  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038019102     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1046/j.1474-7766.2002.00302.x     Document Type: Review

References (32)

1. Amato AA & Barohn RJ (1999) Inflammatory myopathies: dermatomyositis, polymyositis, inclusion body myositis and related diseases. In: Muscle Diseases (eds Schapira AHV & Griggs RC), pp. 299-38. Butterworth Heinemann, Boston.
2. Arahata K & Engel AG (1986) Monoclonal antibody analysis of mononuclear cells in myopathies. III. Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Annals of Neurology, 19, 112-25. (Pubitemid 16114164)
3. Bartoccioni E, Gallucci S, Scuderi F et al. (1994) MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clinical and Experimental Immunology, 95, 166-72. (Pubitemid 24207121)
4. Behrens L, Bender A, Johnson MA & Hohlfeld R (1997) Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibers and inflammatory cells. Brain, 120, 929-38. (Pubitemid 27259544)
5. Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H & Hohlfeld R (1995) T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. Journal of Experimental Medicine, 181, 1863-8.
6. Benveniste O, Cherin P, Maisonobe T et al. (2001) Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. Journal of Immunology, 167, 3521-9. (Pubitemid 32852598)
7. Brouwer R, Hengstman GJ, Vree Egberts W et al. (2001) Autoantibody profiles in the sera of European patients with myositis. Annals of the Rheumatic Diseases, 60, 116-23. (Pubitemid 32102201)
8. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. New England Journal of Medicine, 325, 1487-98.
9. Dalakas MC (1998a) Molecular immunology and genetics of inflammatory muscle diseases. Archives of Neurology, 55, 1509-12
10. Dalakas MC (1998b) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology, 51, S2-S8.
11. Dalakas MC (1998c) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology, 51, S37-S45.
12. Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New England Journal of Medicine, 329, 1993-2000. (Pubitemid 24015043)
13. Dalakas MC & Sivakumar K (1996) The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Current Opinion in Neurology, 9, 235-9. (Pubitemid 26242677)
14. Engel AG, Hohlfeld R & Banker BQ (1994) The polymyositis and dermatomyositis syndromes. In: Myology (eds Engel AG & Franzini-Armstrong C), pp. 1335-83. McGraw-Hill, New York.
15. Feldman M, Taylor P, Paleolog E, Brennan FM & Maini RN (1998) Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplantation Proceedings, 30, 4126-7. (Pubitemid 29013179)
16. Goebels N, Michaelis D, Engelhardt M et al. (1996) Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. Journal of Clinical Investigation, 97, 2905-10. (Pubitemid 26197106)
17. Hall G. (2001) Muscle Biopsy. Practical Neurology, 1, 113-18.
18. Hill CL, Zhang Y, Sigurgeirsson B et al. (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet, 357, 96-100. (Pubitemid 32094911)
19. Hohlfeld R, Engel AG, Ii K & Harper MC (1991) Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. New England Journal of Medicine, 324, 877-81.
20. Hohlfeld R, Michels M, Heininger K, Besinger U & Toyka KV (1988) Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology, 38, 258-61. (Pubitemid 18036849)
21. Lundberg & Chung (2000b) Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology, 39, 7-17.
22. Lundberg I, Kratz AK, Alexanderson H & Patarroyo M (2000a) Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis and Rheumatism, 43, 336-48. (Pubitemid 30395742)
23. Lundberg I, Ulfgren AK, Nyberg P, Andersson U & Klareskog L (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis and Rheumatism, 40, 865-74. (Pubitemid 27200003)
24. Mantegazza R, Bernasconi P, Confalioneri P & Cornelio D (1997) Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. Journal of Neurology, 244, 277-87. (Pubitemid 27212239)
25. Mastaglia FL, Phillips BA & Zilko PJ (1997) Treatment of inflammatory myopathies. Muscle and Nerve, 20, 651-64. (Pubitemid 27197717)
26. Miller FW (1993) Myositis specific autoantibodies. Touchstones for understanding the inflammatory myopathies. JAMA, 270, 1846-9.
27. Miller FW, Leitman SF, Cronin ME et al. (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. New England Journal of Medicine, 326, 1380-4.
28. Pritchard J & Hughes RAC (2001) Intravenous immunoglobulin - how to use it. Practical Neurology, 1, 93-97.
29. Rider LG & Miller FW (1997) Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheumatic Disease Clinics of North America, 23, 619-55. (Pubitemid 27397123)
30. Schneider C, Gold R, Dalakas MC et al. (1996) MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory cT cells: Studies in patients with polymyositis, dermatomyositis and inclusion body myositis. Journal of Neuropathology and Experimental Neurology, 55, 1205-9. (Pubitemid 26397139)
31. Voltz R & Hohlfeld R (1996) The use of intravenous immunoglobulins in the treatment of neuromuscular disorders. Current Opinion in Neurology, 9, 360-6. (Pubitemid 26345190)
32. Zantos D, Zhang Y & Felson D (1994) The overall and temporal association of cancer with polymyositis and dermatomyositis. Journal of Rheumatology, 21, 1855-9. (Pubitemid 24312647)